Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape-Reference-Cited by-同舟云学术

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape

Published:2023-02-01 Issue:2 Volume:16 Page:133-148
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Solana-Altabella Antonio¹²^ORCID,Megías-Vericat Juan Eduardo¹^ORCID,Ballesta-López Octavio¹²^ORCID,Martínez-Cuadrón David²³^ORCID,Montesinos Pau²³^ORCID

Affiliation:

1. Servicio de Farmacia Área del Medicamento, Hospital Universitari i Politècnic La Fe Av. Valencia, Spain

2. Grupo de Investigación en Hematología y Hemoterapia, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain

3. Servicio de Hematología y Hemoterapia Hospital Universitari i Politècnic La Fe. Valencia Spain

Funder

Instituto de Investigación Sanitaria La Fe

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2023.2174523

Reference98 articles.

1. Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents

2. Acute Myeloid Leukemia

3. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

4. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

5. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party